Md Saddam Nawaz discusses four guidances released by the MHRA to help firms navigate the regulatory waters during the COVID-19 pandemic.
Regulatory authorities are engaged in numerous activities to protect and promote public health during the COVID-19 pandemic, ranging from the acceleration of development for treatments for the novel coronavirus, maintaining and securing drug supply chains, providing guidance to manufacturers, advising developers on how to handle clinical trial issues and keeping the public informed.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
This article examines the guidances published by the UK Medicines and Healthcare products Regulatory Agency (MHRA) on Inspections and good practice that can be applied to help pharmaceutical companies cope with the Good laboratory and Distribution Practice consequences of the COVID 19 pandemic, while ensuring a high level of quality, safety and efficacy for medicinal drugs made available to patients.
Guidance 1: Approval of GxP documents when working from home during COVID-19 outbreak
Due to the COVID-19 pandemic, remote or home-based working has increased. This guidance facilitates organisations to consider alternative methods whilst maintaining basic control of GxP documents.
GxP documents can generally be spilt into two categories:
Electronically generated documents
Paper documents.
According to the MHRA guidance, companies utilising validated systems that support electronic signatures approval and are available remotely should continue to use them.
Conversely, documents that have traditionally been printed on paper, physically handed to each reviewer and/or approver in an office and authorised using wet ink signatures can be shared with remote workers, but they have no formal system describing how the review and approval can be recorded. Such documents include, but are not limited to, validation protocols and reports, risk assessments, technical reports, quality management system documents that are paper-based such as standard operating procedures (SOPs), investigations and change requests etc.
Therefore, the MHRA recommends identifying the aspects to consider with remote approval, including:
How the approval signature is attributable to an individual
Whether there is a legislative requirement or GxP guidance for a signature. If there is, then the signature should be considered more critical and have proportionately greater control – for example when a qualified person (QP) certifies a batch of finished product to enable release for sale.
The security of the electronic signature ie, so that it can only be applied by the ‘owner’ of that signature
How the act of ‘signing’ is recorded so that the document cannot be altered or manipulated without invalidating the signature or status of the entry
Ensuring that all required associated data is available to a remote reviewer that would have been available to them if they were performing the review at a site.
Figure 1: Example of remote approval by the MHRA [credit: MHRA].
The guidance urges that the solution will vary from firm to firm, depending on the type of document and the tools available to the person performing the approval – eg, printer, scanner/smartphone, secure email, third party software or existing systems that have tools to capture electronic signatures.
No matter what system or process is used, the following principles should be applied to maintain control:
Controls should be proportionate to the risk considering the type of document and the methods used for distribution and approval
A signature performed remotely should be equivalent to the handwritten signature of the signatory
The method of document distribution and approval should be defined to minimise the risk of error due to misunderstanding what is being reviewed/approved.
Guidance 2: Guidance for manufacturers and Good Practice (GxP) laboratories on exceptional flexibilities for maintenance and calibration during the coronavirus outbreak
The agency is allowing alternative courses of action for manufacturing or laboratory equipment during the outbreak. The following options are available to manufacturers and GxP laboratories to conduct maintenance and calibration during the COVID-19 pandemic.
If an engineer is available to attend site
An organisation’s health and safety procedures or manual should be updated so the engineer can ensure appropriate social distancing measures are upheld and be supervised adequately during their time on site.
Calibration and maintenance protocols or similar documents may be reviewed prior to the engineer visiting the site as per routine requirements. Approval may be given electronically and the site visit documentation may also be signed electronically.
If an engineer cannot attend site but is available by telephone or video call
A qualified employee may perform the calibration or maintenance task under remote supervision from the engineer, providing the site has all the required materials, parts and tools to perform the task.
If an engineer is not available to attend site and remote supervision is not possible
A pharmaceutical quality system record (eg, change control or deviation) should be raised and the delay to the calibration or maintenance task should be risk assessed, considering;
the criticality of the equipment and its intended use
frequency of the calibration/maintenance
whether it is an interim or annual recalibration/maintenance task
prior performance, including ‘drift’ between previous calibration or maintenance visits and recent breakdown history
performance checks that are performed on the equipment prior to use
if alternative equipment is available to perform the task and is within its calibration/maintenance period.
A risk assessment should be performed that considers additional performance checks and verifications to monitor the compliance status of equipment. The delay to a calibration or maintenance task should be documented and handled by the quality management system. Equipment breakdown should also have outstanding maintenance or calibration work completed prior to being put back into use.
Off-site calibration/maintenance
Navigable equipment can be shipped off-site for calibration or maintenance. If this is not standard practice then the firm should detail the risks of equipment leaving the site for calibration or maintenance and examine whether it is fit for the intended use after return to the site.
Substitution of laboratory equipment
Any analytical methods that have been validated/verified on a specific make/model of equipment can be transferred to an equivalent instrument after assessment of the impact on the validated/verified status of the method. If required, method validation/verification may need to be performed again to ensure the validity of the results generated.
Guidance 3: Guidance for Good Laboratory Practice (GLP) facilities in relation to COVID-19
The UK Good Laboratory Practice Monitoring Authority (UK GLPMA) recognises there are potential challenges that COVID-19 will present to members of the GLP monitoring programme.
Office-based GLP inspections
Office-based inspection can be conducted and once the inspection is closed a statement of compliance will be issued to provide that facility with a record of continued membership of the monitoring programme. However, an onsite facility inspection will then be scheduled once the regular inspection programme resumes.
Amendments and deviations
Any incident or deviation encountered due to COVID-19 that could potentially impact the GLP status of a study should be maintained, fully assessed and documented via existing amendment and deviation programme by the firm.
Quality Assurance (QA)
The guidance recommends that QA activities are prioritised using a risk-based approach. A risk assessment can be used to identify where to focus resources and adapt audit programmes. The impact of deviation from planned QA audits or delays due to a lack of resources or travel restrictions should be assessed and documented by the study or quality director.
Remote technology such as video calls can be an alternative to physical presence and would be acceptable. The use of remote observation methods should be fully risk-assessed to ensure they provide a similar level of oversight as a physical audit.
Guidance 4: Exceptional good distribution practice (GDP) flexibilities for medicines during the COVID-19 outbreak
The MHRA’s temporary regulatory flexibilities address the current exceptional circumstances. However, they are being regularly reviewed and may be updated at any time.
Supply chain
Periodic supplier and customer requalification may be postponed. Interim reliance may be placed upon regular review of notifications of suspended wholesale dealer authorisations (WDA(H)) and any General Pharmaceutical Council registration updates. Medicines may be returned to saleable stock if returned from the wholesale distribution chain within 10 days.
Transportation
Non-temperature-controlled transport may be used when the ambient temperature is less than 20°C.
A risk assessment should be in place for products transported under less than 8°C, with justified mitigating measures and with ‘Do not refrigerate’ identification.
Another risk assessment ought to be conducted for products that can be held for up to 96 hours at a transit hub without a WDA(H) to assist in transportation. Alternative arrangements to show proof of delivery will be permitted.
Responsible Persons (RP)
RPs may fill in for RPs from another company, providing the companies are grouped without variation and have an RP registration number issued by the MHRA.
Facilities and equipment
Storage and distribution equipment may be used as soon as possible, supported by a risk assessment and additional mitigating measures with limited qualification and validation. Remaining qualification and validation work should be completed retrospectively, with any delays minimised.
Management of deviations – following assessment by the RP to determine the impact of a deviation or non-conformance, investigation of ‘minor’ events may be put on hold. These should be tracked, with investigations initiated in response to an identified trend.
Post-inspection regulatory commitments relating to deficiencies classified as ‘other’ may be put on hold. These should be recorded in the quality system and corrected after pandemic restrictions are lifted.
Routine Standard Operating Procedure reviews may be extended
Electronic alternatives to wet signatures will be permitted. Distributors should ensure that interim working systems are designed to accommodate data integrity principles.
Internal audit (self-inspection) and GDP refresher training may be put on hold. Training new personnel in GDP principles and training of procedural updates should continue.
The MHRA recognises that the care of patients is every firm’s priority. To achieve this goal and ensure only the highest quality products are manufactured, the MHRA requires that firms make relevant decisions which have been carefully evaluated for risks.
About the author
Md Saddam Nawaz is the Manager of QA at ACI HealthCare Limited, a subsidiary of ACI Limited. His focus is on QbD, data integrity and validation in the field of pharmaceuticals and he is also a GMP and regulatory speaker.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.